Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972

Scrip Asia 100 ebook

Citeline's latest Scrip Asia 100 e-book is live! Visit the microsite to download the report.


Spotlight On Earnings


Focus On Asia


Data Analysis


R&D


Tezspire Phase III Nasal Polyp Data May Lead To Second Indication

Tezspire Phase III Nasal Polyp Data May Lead To Second Indication

 
• By 

AstraZeneca and Amgen’s first-in-class anti-TSLP agent Tezspire, already approved for severe asthma, has shown an ability to reduce the size of nasal polyps and improve congestion.

Zealand’s Amylin Obesity Drug Could Rival Novo’s - But It Needs A Partner

Zealand’s Amylin Obesity Drug Could Rival Novo’s - But It Needs A Partner

 

The Danish company believes amylin analog petrelintide can compete with GLP-1 agonists – and hopes an imminent Phase III readout from Novo Nordisk’s rival drug will give it a boost too.

Ionis Looks Ahead To Commercializing Its Own Products

Ionis Looks Ahead To Commercializing Its Own Products

 
• By 

Beyond its cardiovascular partnership with AstraZeneca, Ionis is getting ready to launch antisense drugs for familial chylomicronemia syndrome and hereditary angioedema.

ASH ’24: Arcellx Mounts Strong Challenge To Myeloma CAR-T Rival Carvykti

ASH ’24: Arcellx Mounts Strong Challenge To Myeloma CAR-T Rival Carvykti

 

The biotech’s challenger CAR-T is matching Carvytki in efficacy and showing an edge in safety in abstract data released ahead of the December meeting.

Business


Profile: MSD, Janssen To BSV-Mankind Deal, Navangul’s Journey Is A Rich Mosaic

Profile: MSD, Janssen To BSV-Mankind Deal, Navangul’s Journey Is A Rich Mosaic

 

Ex-Janssen India chief and BSV CEO Sanjiv Navangul shares with Scrip glimpses of his life and professional journey including chasing the IAS dream early on, the heady days at Hoechst with a stint in Moscow, challenges around Sirturo’s debut and unprecedented preps that fueled Januvia’s big run during his innings at MSD.

Europe Biotech Sector Superb At Science But Still Scared To Take Risks

Europe Biotech Sector Superb At Science But Still Scared To Take Risks

 
• By 

Medixci’s Nick Williams told attendees at BIO-Europe that it was a shame that promising biotechs head to the NASDAQ as soon as possible. He and called for a change in culture from investors and for them to back the continent’s start-ups with proper funding.

Wegovy In The Wings, Novo Outlines Potential, Sizes Up Perceptions In India

Wegovy In The Wings, Novo Outlines Potential, Sizes Up Perceptions In India

 

Novo Nordisk India MD talks to Scrip about what to expect when Wegovy arrives in India and the local trajectory of Rybelsus. The Danish group also shared findings of a study around obesity.

Scrip Originals


Deal Watch: Renexxion To Go Public While Avid Biosciences Goes Private

Deal Watch: Renexxion To Go Public While Avid Biosciences Goes Private

 
• By 

Plus deals involving Synaffix/BigHat, AbbVie/EvolveImmune, Servier/Aitia, Dr. Falk/Kynos, Bayer/Dewpoint and more.

Executives On The Move: Five CEOs And Four New CFOs Among This Week’s Changes

Executives On The Move: Five CEOs And Four New CFOs Among This Week’s Changes

 
• By 

Recent moves in the industry include C-suite changes at Coya Therapeutics, Kancera and Verrica Pharmaceuticals, which acquires chief financial officer from Aceragen.

Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals

Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals

 
• By 

Public Company Edition: Syndax received all $350m from its royalty financing up front, while KalVista got $100m initially out of up to $179m. Also, Vera, EyePoint and Eledon grossed $300m, $161m and $85m in follow-on offerings, while Neurogene raised $200m in a private placement.

Stock Watch: Sanofi’s Seasonal Surge And Novartis’s Material Write-Down

Stock Watch: Sanofi’s Seasonal Surge And Novartis’s Material Write-Down

 
• By 

Investors’ different responses to third-quarter sales growth at Sanofi and Novartis left future seasonal sales trends and past business development activity under scrutiny.